GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] can we stop arguing about STEP until somebody posts a number — 15 comments in the full submission. View in context.
247
c/trialwatch·submitted 2 years ago by u/yannick_salinas

[Discussion] can we stop arguing about STEP until somebody posts a number

Discussionbranch of 9 comments

STEP. That is the whole post, but I will justify it. Everything else people worry about in c/orforglipron is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does. I say this having got it wrong for 5 months. My…

Read the full submission and all 15 comments →

This branch

9 comments, started 2 years ago
u/joaquin_stanescu16 points·2 years ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/yannick_salinasOP12 points·2 years ago

Half-life is about 168 hours, so steady state lands around week 22–5. Practical consequence: what you feel in week 1 is not what that dose does.

replysharereportpermalink
u/aurel_mwangi6 points·2 years ago

Half-life is about 168 hours, so steady state lands around week 22–5.

Yes, exactly this, and it is the bit that took me 23 weeks to accept.

replysharereportpermalink
u/adaeze_weiss9 points·2 years ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/laila_almeida4 points·2 years ago

the discontinuation arms are the interesting part, not the endpoint endpoints

replysharereportpermalink
u/tove_ogunleye3 points·2 years ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/cloudy_vial_carol5 points·2 years ago

Strongly agree.

Disagree on that part. 98.4% and 98.3% on the same vial is normal.

replysharereportpermalink
u/oskar_ibarra6 points·2 years ago

Phase 2 or phase 3?

replysharereportpermalink
u/yannick_salinasOP4 points·2 years ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.